Capital reduction

RNS Number : 0605L
Byotrol PLC
08 January 2021
 

 

 

 

 

 

8 January 2021

Byotrol Plc

 

("Byotrol" or the "Group")

 

Capital reduction

 

 

Byotrol plc (AIM: BYOT), the anti-microbial technology company, announces that on 8 December 2020 the High Court issued an order confirming the cancellation of the Company's share premium account and the B shares issued by the Company to capitalise the amount standing to the credit of the merger reserve of the Company ("the Capital Reduction"). Following registration with Companies House, the Capital Reduction became effective on 7 January 2021.

 

For further information contact:

 

Byotrol Plc

 

David Traynor, Chief Executive

+44 (0)1925 742 000

Nic Hellyer, Chief Financial Officer

 

 

 

finnCap Limited (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Geoff Nash/Kate Bannatyne - Corporate Finance

 

Richard Chambers - ECM

 

 

 

Flagstaff Strategic and Investor Communications

+44 (0)20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon  

 

byotrol@flagstaffcomms.com

 

 

 

Notes to editors

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to byotrol.co.uk

 

 

 [END]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPUCWGUPGUBR
UK 100

Latest directors dealings